
Please try another search
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert for determining smoking status; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.
Name | Age | Since | Title |
---|---|---|---|
David S. Morse | 68 | 2006 | Independent Director |
Paul Averback | 74 | 1995 | Founder, Chairman, CEO & President |
James G. Robinson | 90 | 2015 | Independent Director |
Patrick A. Doody | 62 | 2023 | VP, General Counsel & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review